REGENXBIO Inc. (NASDAQ: RGNX) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT REGENXBIO INC.

REGENXBIO Inc. (NASDAQ: RGNX)
Listen to this Section


$6.89
+0.2000 ( +2.99% ) 831.1K

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Clinical Trial Pipeline Stages


Drug Name Stage
ABBV-RGX-314 (Suprachoroidal Delivery)DetailsEye disease , Age-related macular degeneration, Wet age-related macular degeneration Phase 2
ABBV-RGX-314 (Subretinal Delivery)DetailsEye disease , Wet age-related macular degeneration , Age-related macular degeneration Phase 2
ABBV-RGX-314 (Suprachoroidal Delivery)DetailsDiabetes, Eye disease , Diabetic retinopathy Phase 2
RGX-202DetailsGenetic disorder, Rare diseases, Rare genetic disease, Duchenne muscular dystrophy Phase 1/2
RGX-381DetailsCentral nervous system illness Phase 1/2
RGX-111DetailsMucopolysaccharidoses, Rare genetic disease, Genetic disorder, Rare diseases, Mucopolysaccharidosis Type 1 Phase 1/2
RGX-181DetailsCentral nervous system illness, Batten Disease Phase 1
RGX-202DetailsRare diseases, Genetic disorder, Rare genetic disease, Duchenne muscular dystrophy Phase 2/3

Market Data


Open $6.89
Previous Close $6.69
Volume 831.1K
Market Cap $345.86M
Day Range $6.55 - $7.18
52 Week Range $5.46 - $16.19
Shares Outstanding 51.70M
Change % +2.99%
Net Change ▲ 0.2000
Insider Ownership -0.04%
Exchange NASDAQ
SectorHealthcare
IndustryBiotechnology
IPO Year2015
CountryUnited States
UnderwriterIPO Intelligence Only

Insider Ownership Transactions

Total Amount Purchased: -524,894.00

Date Type Amount Purchased Purchaser
2024-01-04 Sale -4534.00 Vasista Vittal
2024-01-04 Sale -11357.00 Mills Kenneth T.
2024-01-04 Sale -7893.00 Christmas Patrick J.
2023-12-21 Sale -43500.00 Mills Kenneth T.

SEC Filings


Form Type Description Pages Date
8-k 8K-related 12 Nov 06, 2025
10-q Quarterly Reports 82 Nov 06, 2025
4 Insider transactions 1 Oct 10, 2025
4 Insider transactions 1 Oct 01, 2025
4 Insider transactions 1 Sep 12, 2025
4 Insider transactions 1 Sep 03, 2025
4 Insider transactions 1 Sep 03, 2025
8-k 8K-related 12 Aug 18, 2025
10-q Quarterly Reports 84 Aug 07, 2025
8-k 8K-related 14 Aug 07, 2025

Latest News


× Before browsing our site, please accept our cookies policy